News Grail's multi-cancer test fluffs its lines in UK trial Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.
News Grail multi-cancer test taps into Hims & Hers network Grail has teamed up with telehealth company Hims & Hers to boost access to its recently filed Galleri blood test for cancer screening.
News UK start-up Procyon has pancreatic cancer test in its sights Procyon is hoping to launch a diagnostic test next year that will be able to detect people at risk of pancreatic cancer from a urine sample.
News ESMO: Grail's data on cancer blood test firms up Data from a new phase 3 trial of Grail's blood test for multiple cancers show improved efficacy and a lower rate of false alarms than a prior study.
R&D Precision medicine - closing the loop: What happens after th... We often talk about diagnostics as the gateway to precision medicine. But what happens before and after the test?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.